Novartis

Novartis Indonesia

Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives. Novartis works closely with healthcare professionals around the world to support ...
Novartis

Pretraga otvorenih pozicija

Tehnik v proizvodnji farmacevtskih učinkovin (m/ž/d) Temporary (Fixed Term) Slovenia Mengeš Dec 04, 2025 ...
Novartis

Product Listing in Singapore

Below is a list of the treatments we currently offer via our Innovative Medicines Division. Visit Sandoz and Advanced Accelerator Applications to learn about our generics and radiopharmaceutical ...
Novartis

Novartis provides update on production of radioligand therapy medicines

Novartis has temporarily suspended production of Lutathera® and Pluvicto™/ 177Lu-PSMA-617 at facilities in Ivrea, Italy and Millburn, New Jersey This action has been taken out of an abundance of ...
Novartis

FDA approves Xolair® (omalizumab) as first and only medicine for children and adults with one or more food allergies

Approval is based on data from the NIH-sponsored Phase III OUtMATCH study, which showed a significantly higher proportion of food allergy patients as young as 1 year treated with Xolair could tolerate ...
Novartis

Novartis completes acquisition of Tourmaline Bio

. Novartis is providing the information in this press release as of this date, and Novartis does not undertake any obligation to update any forward-looking statements contained in this press release ...
Novartis

Novartis receives EC approval for Enerzair® Breezhaler®, including the first digital companion (sensor and app) that can be prescribed alongside a treatment for uncontrolled ...

Asthma affects an estimated 358 million people worldwide and can cause a significant personal, health and financial burden when not adequately controlled 3,4 “Novartis is working to reimagine medicine ...
Novartis

Novartis expands its biopharmaceutical manufacturing site in Singapore

Invests US$256 million to expand biopharmaceutical manufacturing facility in Singapore, addressing the soaring demand in the Asian market Set to generate 100 high skilled employment opportunities in ...
Novartis

Novartis to acquire Gyroscope Therapeutics, adding a one-time gene therapy that could transform care for geographic atrophy, a leading cause of blindness

There are no currently approved therapies impacting disease progression for the up to 8 million people suffering from geographic atrophy (GA) 1,2 Acquisition will add GT005 to the Novartis portfolio, ...
Novartis

Novartis completes divestment of ‘front of eye’ ophthalmology assets

Divestment includes Xiidra®, on-market treatment for dry eye disease and additional ophthalmic investigational therapies Novartis advances strategy of focused portfolio and prioritized therapeutic ...
Novartis

Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials

Basel, October 29, 2025 – Novartis today presented new ianalumab data in Sjögren’s disease, the second most prevalent rheumatic autoimmune disease 2, at a late-breaker presentation during the American ...
Novartis

Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)

Basel, August 8, 2024 – Novartis today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Fabhalta ® (iptacopan), a first-in-class complement inhibitor for ...